MiPT

MiPT
Clinical data
Other names	MiPT; N-Methyl-N-isopropyltryptamine
Routes of; administration	Oral
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code	None;
Legal status
Legal status	AU: Unscheduled; CA: Unscheduled; DE: NpSG (Industrial and scientific use only); UK: Class A; US: Unscheduled;
Pharmacokinetic data
Onset of action	Oral: 30 minutes; Insufflation: <1 minute
Duration of action	3–4 hours
Identifiers
	IUPAC name N-[2-(1H-indol-3-yl)ethyl]-N-methylpropan-2-amine;
CAS Number	96096-52-5;
PubChem CID	29935323;
ChemSpider	21106353 ;
UNII	JO3SCR302A;
ChEMBL	ChEMBL353728 ;
CompTox Dashboard (EPA)	DTXSID901024777 ;
Chemical and physical data
Formula	C14H20N2
Molar mass	216.328 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)N(C)CCc1c[nH]c2ccccc12;
	InChI InChI=1S/C14H20N2/c1-11(2)16(3)9-8-12-10-15-14-7-5-4-6-13(12)14/h4-7,10-11,15H,8-9H2,1-3H3 ; Key:KTQJVAJLJZIKKD-UHFFFAOYSA-N ;
	(verify)

Methylisopropyltryptamine (MiPT), also known as N-methyl-N-isopropyltryptamine, is a psychedelic drug of the tryptamine family related to other psychedelics like dimethyltryptamine (DMT) and diisopropyltryptamine (DiPT). It is taken orally.

The drug acts as a serotonin receptor modulator, including as an agonist of the serotonin 5-HT_2A receptor. Derivatives of MiPT include 4-HO-MiPT (miprocin) and 5-MeO-MiPT (moxy).

MiPT was first described by David Repke and colleagues in 1981. It was subsequently evaluated and described in Alexander Shulgin's 1997 book TiHKAL (Tryptamines I Have Known and Loved). MiPT was encountered as a novel designer drug by 2005.